Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 ALDX | Healthcare | $0.64 | 764.02K | $38.03M | -2.02 | ― | Hold |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ALDX | Aldeyra Therapeutics | 0.64 | -4.41 | -87.27% |
| Name | Price | % Change | |
|---|---|---|---|
| ALDX | $0.64 | -87.27% |
Aldeyra Therapeutics ( ($ALDX) ) just unveiled an announcement. On November 9, 2026, Aldeyra requested that the FDA’s Division of Ophthalmology ask the Office of New Drugs to transfer review
Analyst Matthew Caufield of H.C. Wainwright reiterated a Hold rating on Aldeyra Therapeutics, retaining the price target of $2.00. Matthew Caufield has given his Hold rating due to a combination
Aldeyra Therapeutics ( ($ALDX) ) has issued an update. On September 25, 2026, Aldeyra Therapeutics held a Type D meeting with the U.S. Food and Drug Administration regarding reproxalap for
Aldeyra (ALDX) Therapeutics announced intent to submit to the U.S. Food and Drug Administration a Formal Dispute Resolution Request for reproxalap, an investigational drug candidate, for the treatment of dry
Based on reported cash and cash equivalents of $45.1M as of June 30, 2026, Aldeyra (ALDX) updated financial guidance to include extension of operational cash runway into 2029. Published first
Matthew Caufield, an analyst from H.C. Wainwright, reiterated the Hold rating on Aldeyra Therapeutics. The associated price target is $2.00. Matthew Caufield has given his Hold rating due to a
Aldeyra Therapeutics ( ($ALDX) ) just unveiled an update. On July 28, 2026, Aldeyra Therapeutics executed a lease agreement with Bradford Street, L.L.C. for approximately 4,067 square feet of office
Aldeyra Therapeutics (ALDX) is scheduled to report 2nd quarter earnings on 07/31/2026. Regarding Q2 estimates, Wall Street analysts expect Aldeyra Therapeutics to post earnings of -$0.08 per share. Last quarter,
The latest update is out from Aldeyra Therapeutics ( ($ALDX) ). On June 9, 2026, following its annual meeting of stockholders, Aldeyra Therapeutics appointed veteran biotech executive Darlene Deptula-Hicks as
A class action lawsuit was filed against Aldeyra Therapeutics ($ALDX) on March 30, 2026. Plaintiffs in the federal securities lawsuit allege that they acquired Aldeyra stock at artificially inflated prices
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| ALDX | May 6, 2027TBA | $38.03M | ― | ― | 0.23 | -2.02 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
